Selected research
Market Structure
Global Parkinson's Disease Treatments Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Parkinson's Disease Treatments market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Parkinson's Disease Treatments is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Parkinson's Disease Treatments is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Parkinson's Disease Treatments is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Parkinson's Disease Treatments is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Parkinson's Disease Treatments include GSK, Teva, Sun Pharma, Novartis, Merck, Abbvie, Wockhardt, UCB and Lundbeck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Parkinson's Disease Treatments market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Parkinson's Disease Treatments and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Parkinson's Disease Treatments revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Parkinson's Disease Treatments market size, projected growth trends, production technologies, key applications, and end-use industries.
Parkinson's Disease Treatments Segment by Company
GSK
Teva
Sun Pharma
Novartis
Merck
Abbvie
Wockhardt
UCB
Lundbeck
Impax
Boehringer Ingelheim
Bausch Health
Acadia
Parkinson's Disease Treatments Segment by Type
COMT Inhibitors Anticholinergics
MAO-B Inhibitors
Apomorphine
Dopamine Agonists
Glutamate Antagonist
Levodopa
Other Drugs
Parkinson's Disease Treatments Segment by Application
Hospitals
Healthcare Institutes
Others
Parkinson's Disease Treatments Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Parkinson's Disease Treatments market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Parkinson's Disease Treatments and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Parkinson's Disease Treatments.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Parkinson's Disease Treatments in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Parkinson's Disease Treatments industry.
Chapter 3: Detailed analysis of Parkinson's Disease Treatments companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Parkinson's Disease Treatmentsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- COMT Inhibitors Anticholinergics
- MAO-B Inhibitors
- Apomorphine
- Dopamine Agonists
- Glutamate Antagonist
- Levodopa
- Other Drugs
Applications
- Hospitals
- Healthcare Institutes
- Others
Companies covered
- GSK
- Teva
- Sun Pharma
- Novartis
- Merck
- Abbvie
- Wockhardt
- UCB
- Lundbeck
- Impax
- Boehringer Ingelheim
- Bausch Health
- Acadia
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Parkinson's Disease Treatments Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 COMT Inhibitors Anticholinergics
- 1.2.3 MAO-B Inhibitors
- 1.2.4 Apomorphine
- 1.2.5 Dopamine Agonists
- 1.2.6 Glutamate Antagonist
- 1.2.7 Levodopa
- 1.2.8 Other Drugs
- 1.3 Market Analysis by Application
- 1.3.1 Global Parkinson's Disease Treatments Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hospitals
- 1.3.3 Healthcare Institutes
- 1.3.4 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global Parkinson's Disease Treatments Growth Trends by Region
- 1.5.1 Global Parkinson's Disease Treatments Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Parkinson's Disease Treatments Market Size by Region (2021-2026)
- 1.5.3 Parkinson's Disease Treatments Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Parkinson's Disease Treatments Market Dynamics
- 2.1 Parkinson's Disease Treatments Industry Trends
- 2.2 Parkinson's Disease Treatments Industry Drivers
- 2.3 Parkinson's Disease Treatments Industry Opportunities and Challenges
- 2.4 Parkinson's Disease Treatments Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Parkinson's Disease Treatments Revenue by Company (2021-2026)
- 3.2 Global Parkinson's Disease Treatments Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Parkinson's Disease Treatments Key Company Head office and Area Served
- 3.4 Global Parkinson's Disease Treatments Company, Product Type & Application
- 3.5 Global Parkinson's Disease Treatments Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Parkinson's Disease Treatments Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Parkinson's Disease Treatments Players Market Share by Revenue in 2025
- 3.6.3 2025 Parkinson's Disease Treatments Tier 1, Tier 2, and Tier 3
4 Parkinson's Disease Treatments Market by Type
- 4.1 Global Parkinson's Disease Treatments Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Parkinson's Disease Treatments Market Size by Type (2021-2032)
- 4.3 Global Parkinson's Disease Treatments Market Size Share by Type (2021-2032)
5 Parkinson's Disease Treatments Market by Application
- 5.1 Global Parkinson's Disease Treatments Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Parkinson's Disease Treatments Market Size by Application (2021-2032)
- 5.3 Global Parkinson's Disease Treatments Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 GSK
- 6.1.1 GSK Company Information
- 6.1.2 GSK Business Overview
- 6.1.3 GSK Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 GSK Parkinson's Disease Treatments Product Portfolio
- 6.1.5 GSK Recent Developments
- 6.2 Teva
- 6.2.1 Teva Company Information
- 6.2.2 Teva Business Overview
- 6.2.3 Teva Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Teva Parkinson's Disease Treatments Product Portfolio
- 6.2.5 Teva Recent Developments
- 6.3 Sun Pharma
- 6.3.1 Sun Pharma Company Information
- 6.3.2 Sun Pharma Business Overview
- 6.3.3 Sun Pharma Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Sun Pharma Parkinson's Disease Treatments Product Portfolio
- 6.3.5 Sun Pharma Recent Developments
- 6.4 Novartis
- 6.4.1 Novartis Company Information
- 6.4.2 Novartis Business Overview
- 6.4.3 Novartis Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Novartis Parkinson's Disease Treatments Product Portfolio
- 6.4.5 Novartis Recent Developments
- 6.5 Merck
- 6.5.1 Merck Company Information
- 6.5.2 Merck Business Overview
- 6.5.3 Merck Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Merck Parkinson's Disease Treatments Product Portfolio
- 6.5.5 Merck Recent Developments
- 6.6 Abbvie
- 6.6.1 Abbvie Company Information
- 6.6.2 Abbvie Business Overview
- 6.6.3 Abbvie Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Abbvie Parkinson's Disease Treatments Product Portfolio
- 6.6.5 Abbvie Recent Developments
- 6.7 Wockhardt
- 6.7.1 Wockhardt Company Information
- 6.7.2 Wockhardt Business Overview
- 6.7.3 Wockhardt Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Wockhardt Parkinson's Disease Treatments Product Portfolio
- 6.7.5 Wockhardt Recent Developments
- 6.8 UCB
- 6.8.1 UCB Company Information
- 6.8.2 UCB Business Overview
- 6.8.3 UCB Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 UCB Parkinson's Disease Treatments Product Portfolio
- 6.8.5 UCB Recent Developments
- 6.9 Lundbeck
- 6.9.1 Lundbeck Company Information
- 6.9.2 Lundbeck Business Overview
- 6.9.3 Lundbeck Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Lundbeck Parkinson's Disease Treatments Product Portfolio
- 6.9.5 Lundbeck Recent Developments
- 6.10 Impax
- 6.10.1 Impax Company Information
- 6.10.2 Impax Business Overview
- 6.10.3 Impax Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Impax Parkinson's Disease Treatments Product Portfolio
- 6.10.5 Impax Recent Developments
- 6.11 Boehringer Ingelheim
- 6.11.1 Boehringer Ingelheim Company Information
- 6.11.2 Boehringer Ingelheim Business Overview
- 6.11.3 Boehringer Ingelheim Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Boehringer Ingelheim Parkinson's Disease Treatments Product Portfolio
- 6.11.5 Boehringer Ingelheim Recent Developments
- 6.12 Bausch Health
- 6.12.1 Bausch Health Company Information
- 6.12.2 Bausch Health Business Overview
- 6.12.3 Bausch Health Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Bausch Health Parkinson's Disease Treatments Product Portfolio
- 6.12.5 Bausch Health Recent Developments
- 6.13 Acadia
- 6.13.1 Acadia Company Information
- 6.13.2 Acadia Business Overview
- 6.13.3 Acadia Parkinson's Disease Treatments Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Acadia Parkinson's Disease Treatments Product Portfolio
- 6.13.5 Acadia Recent Developments
7 North America
- 7.1 North America Parkinson's Disease Treatments Market Size (2021-2032)
- 7.2 North America Parkinson's Disease Treatments Market Size by Type
- 7.2.1 North America Parkinson's Disease Treatments Market Size by Type (2021-2026)
- 7.2.2 North America Parkinson's Disease Treatments Market Size by Type (2027-2032)
- 7.2.3 North America Parkinson's Disease Treatments Market Share by Type (2021-2032)
- 7.3 North America Parkinson's Disease Treatments Market Size by Application
- 7.3.1 North America Parkinson's Disease Treatments Market Size by Application (2021-2026)
- 7.3.2 North America Parkinson's Disease Treatments Market Size by Application (2027-2032)
- 7.3.3 North America Parkinson's Disease Treatments Market Share by Application (2021-2032)
- 7.4 North America Parkinson's Disease Treatments Market Size by Country
- 7.4.1 North America Parkinson's Disease Treatments Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Parkinson's Disease Treatments Market Size by Country (2021-2026)
- 7.4.3 North America Parkinson's Disease Treatments Market Size by Country (2027-2032)
- 7.4.4 North America Parkinson's Disease Treatments Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Parkinson's Disease Treatments Market Size (2021-2032)
- 8.2 Europe Parkinson's Disease Treatments Market Size by Type
- 8.2.1 Europe Parkinson's Disease Treatments Market Size by Type (2021-2026)
- 8.2.2 Europe Parkinson's Disease Treatments Market Size by Type (2027-2032)
- 8.2.3 Europe Parkinson's Disease Treatments Market Share by Type (2021-2032)
- 8.3 Europe Parkinson's Disease Treatments Market Size by Application
- 8.3.1 Europe Parkinson's Disease Treatments Market Size by Application (2021-2026)
- 8.3.2 Europe Parkinson's Disease Treatments Market Size by Application (2027-2032)
- 8.3.3 Europe Parkinson's Disease Treatments Market Share by Application (2021-2032)
- 8.4 Europe Parkinson's Disease Treatments Market Size by Country
- 8.4.1 Europe Parkinson's Disease Treatments Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Parkinson's Disease Treatments Market Size by Country (2021-2026)
- 8.4.3 Europe Parkinson's Disease Treatments Market Size by Country (2027-2032)
- 8.4.4 Europe Parkinson's Disease Treatments Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Parkinson's Disease Treatments Market Size (2021-2032)
- 9.2 China Parkinson's Disease Treatments Market Size by Type
- 9.2.1 China Parkinson's Disease Treatments Market Size by Type (2021-2026)
- 9.2.2 China Parkinson's Disease Treatments Market Size by Type (2027-2032)
- 9.2.3 China Parkinson's Disease Treatments Market Share by Type (2021-2032)
- 9.3 China Parkinson's Disease Treatments Market Size by Application
- 9.3.1 China Parkinson's Disease Treatments Market Size by Application (2021-2026)
- 9.3.2 China Parkinson's Disease Treatments Market Size by Application (2027-2032)
- 9.3.3 China Parkinson's Disease Treatments Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Parkinson's Disease Treatments Market Size (2021-2032)
- 10.2 Asia Parkinson's Disease Treatments Market Size by Type
- 10.2.1 Asia Parkinson's Disease Treatments Market Size by Type (2021-2026)
- 10.2.2 Asia Parkinson's Disease Treatments Market Size by Type (2027-2032)
- 10.2.3 Asia Parkinson's Disease Treatments Market Share by Type (2021-2032)
- 10.3 Asia Parkinson's Disease Treatments Market Size by Application
- 10.3.1 Asia Parkinson's Disease Treatments Market Size by Application (2021-2026)
- 10.3.2 Asia Parkinson's Disease Treatments Market Size by Application (2027-2032)
- 10.3.3 Asia Parkinson's Disease Treatments Market Share by Application (2021-2032)
- 10.4 Asia Parkinson's Disease Treatments Market Size by Country
- 10.4.1 Asia Parkinson's Disease Treatments Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Parkinson's Disease Treatments Market Size by Country (2021-2026)
- 10.4.3 Asia Parkinson's Disease Treatments Market Size by Country (2027-2032)
- 10.4.4 Asia Parkinson's Disease Treatments Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Parkinson's Disease Treatments Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Parkinson's Disease Treatments Market Size by Type
- 11.2.1 South America, Middle East & Africa Parkinson's Disease Treatments Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Parkinson's Disease Treatments Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Parkinson's Disease Treatments Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Parkinson's Disease Treatments Market Size by Application
- 11.3.1 South America, Middle East & Africa Parkinson's Disease Treatments Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Parkinson's Disease Treatments Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Parkinson's Disease Treatments Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Parkinson's Disease Treatments Market Size by Country
- 11.4.1 South America, Middle East & Africa Parkinson's Disease Treatments Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Parkinson's Disease Treatments Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Parkinson's Disease Treatments Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Parkinson's Disease Treatments Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst